Sobi gets US FDA Fast Track for pacritinib in VEXAS
Sobi North America said the US FDA granted Fast Track designation to pacritinib for treatment of VEXAS syndrome.
Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), said the US Food and Drug Administration has granted Fast Track designation to pacritinib for the treatment of VEXAS syndrome. The company said the designation was announced on Sept. 09, 2026.